Skip to search formSkip to main contentSkip to account menu

CS-514

Known as: CS 514, CS514 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

PravastatinPravastatin Sodium

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1990
1990
Effect of pravastatin sodium, a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on very-low-density lipoprotein composition and kinetics in hyperlipidemia associated with…
1990
1990
The effect of HMG-CoA reductase inhibitor (CS-514) on the synthesis and secretion of apolipoproteins B and A-1 in the human hepatoblastoma Hep G2.
Review
1989
Review
1989
Biochemical aspect of HMG CoA reductase inhibitors.
1989
1989
Long-term treatment of hypercholesterolemic non-insulin dependent diabetics (NIDDM) with pravastatin (CS-514).
1988
1988
Effect of CS-514 (pravastatin) on VLDL-triglyceride kinetics in rats.
1988
1988
Dose-dependent hypolipidemic effect of an inhibitor of HMG-CoA reductase, pravastatin (CS-514), in hypercholesterolemic subjects. A double blind test.
1988
1988
Effects of CS-514 on plasma lipids and lipoprotein composition in hypercholesterolemic subjects.
1987
1987
Effect of CS-514 on Hypercholesterolemic Patients
The efficacy and adverse effects of CS-514 have been studied in the phase II trial conducted in Japan. 
1987
1987
Long-term effect of CS-514 (HMG-CoA reductase inhibitor) on serum lipids, lipoproteins, and apolipoproteins in patinets with hypercholesterolemia
1986
1986
Effects of CS-514, a new inhibitor of HMG CoA reductase, on plasma lipids, lipoproteins and apoproteins in patients with primary hypercholesterolemia.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)